Business Description
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Business History
Price Overview
Last updated: Jun 27, 2026 9:06am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -35.25
Total Equity: $20.63M
Shares: 1,330,200
Total Debt: $574,301
Cash: $11.88M
EBITDA: -$47.41M
Total Debt: $574,301
Cash: $11.88M
Revenue: $622,489
Shares: 1,330,200
Revenue: $622,489
Revenue: $622,489
Revenue: $622,489
Total Equity: $20.63M
Tax Rate: 3.3%
Equity: $20.63M
Total Debt: $574,301
Cash: $11.88M
Current Liabilities: $3.54M
Long-Term Debt: $574,301
Total Debt: $574,301
Total Equity: $20.63M
Shares: 1,330,200
Shares: 1,330,200
CapEx: -$700,047
Shares: 1,330,200
Stock Price: $3.06
Net Income: -$46.90M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 24, 2026 12:32pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $97.9M | $34.2M | $6.8M | $3.9M | $622,489 |
| Cost of Revenue | $11.6M | $5.5M | $4.2M | $999,124 | $222,377 |
| Gross Profit | $86.3M | $28.7M | $2.6M | $2.9M | $400,112 |
| Operating Expenses | $40.2M | $55.7M | $45.3M | $43.0M | $31.7M |
| Operating Income | $46.1M | -$27.0M | -$42.7M | -$40.1M | -$31.3M |
| Net Income | $36.7M | -$14.2M | -$35.3M | -$37.6M | -$46.9M |
| EBITDA | $46.0M | -$10.3M | -$36.9M | -$36.2M | -$47.4M |
| EPS | $38.10 | $-13.57 | $-36.00 | $-37.20 | $-35.25 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 12:32pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $88.6M | $23.0M | $14.9M | $2.9M | $11.9M |
| Total Current Assets | $115.1M | $92.7M | $62.1M | $32.3M | $13.7M |
| Total Assets | $160.0M | $123.1M | $95.3M | $64.0M | $24.7M |
| Current Liabilities | $12.6M | $3.9M | $5.7M | $7.3M | $3.5M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $574,301 |
| Total Liabilities | $25.6M | $8.6M | $9.3M | $9.7M | $4.1M |
| Total Equity | $134.5M | $114.5M | $86.0M | $54.3M | $20.6M |
| Retained Earnings | $54.2M | $39.9M | $4.6M | -$33.0M | -$80.4M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 12:32pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $41.1M | $6.6M | -$22.1M | -$29.2M | -$29.1M |
| Capital Expenditure | $-669,463 | -$1.4M | -$1.4M | $-748,352 | $-700,047 |
| Free Cash Flow | $40.4M | $5.1M | -$23.4M | -$29.9M | -$29.8M |
| Acquisitions (net) | $1.7M | $0 | $0 | $-143,750 | $-102,566 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | -$14.2M | -$1.4M | $0 | $0 |
| Net Change in Cash | $45.6M | -$65.6M | -$8.1M | -$12.0M | $8.9M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 10:35pm (10h ago)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$552,400 $552,400 – $552,400
|
$17.2M $17.2M – $17.2M
|
$59.4M $59.4M – $59.4M
|
$136.6M $136.6M – $136.6M
|
| EBITDA |
$-312,837 $-312,837 – $-312,837
|
-$9.7M -$9.7M – -$9.7M
|
-$33.6M -$33.6M – -$33.6M
|
-$77.4M -$77.4M – -$77.4M
|
| Net Income |
-$16.2M -$16.2M – -$16.2M
|
-$16.0M -$16.0M – -$16.0M
|
-$9.2M -$9.2M – -$9.2M
|
$8.8M $8.8M – $8.8M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 12:32pm (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -65.0% | -80.1% | -42.5% | -84.1% |
| Gross Profit Growth | -66.7% | -90.9% | +11.0% | -86.3% |
| Operating Income Growth | -158.6% | -58.3% | +6.1% | +22.0% |
| Net Income Growth | -138.8% | -148.2% | -6.5% | -24.6% |
| EBITDA Growth | -122.4% | -257.8% | +1.8% | -30.9% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-23 | Egan Dwight H | A-Award | 4,584.00 | $0.00 | $0 |
| 2026-05-23 | Egan Dwight H | D-Return | 1,633.00 | $5.07 | $8,279 |
| 2026-05-23 | Egan Dwight H | M-Exempt | 4,584.00 | $0.00 | $0 |
| 2026-05-23 | Brown Brian Lee | A-Award | 3,750.00 | $0.00 | $0 |
| 2026-05-23 | Brown Brian Lee | D-Return | 1,350.00 | $5.07 | $6,845 |
| 2026-05-23 | Brown Brian Lee | M-Exempt | 3,750.00 | $0.00 | $0 |
| 2026-05-23 | Abbott Richard David | M-Exempt | 1,890.00 | $0.00 | $0 |
| 2026-05-23 | Abbott Richard David | A-Award | 1,890.00 | $0.00 | $0 |
| 2026-05-23 | Abbott Richard David | D-Return | 680.00 | $5.07 | $3,448 |
| 2026-05-23 | Murphy Edward L. | A-Award | 1,695.00 | $0.00 | $0 |
| 2026-05-23 | Murphy Edward L. | M-Exempt | 1,695.00 | $0.00 | $0 |
| 2026-05-23 | SERBIN RICHARD S | A-Award | 1,695.00 | $0.00 | $0 |
| 2026-05-23 | SERBIN RICHARD S | M-Exempt | 1,695.00 | $0.00 | $0 |
| 2026-05-23 | Durenard Eugene | A-Award | 1,695.00 | $0.00 | $0 |
| 2026-05-23 | Durenard Eugene | M-Exempt | 1,695.00 | $0.00 | $0 |
| 2026-05-23 | NELSON JAMES B | A-Award | 1,695.00 | $0.00 | $0 |
| 2026-05-23 | NELSON JAMES B | M-Exempt | 1,695.00 | $0.00 | $0 |
| 2025-11-23 | Murphy Edward L. | A-Award | 57,499.00 | $0.00 | $0 |
| 2025-11-23 | Murphy Edward L. | M-Exempt | 57,499.00 | $0.00 | $0 |
| 2025-11-23 | Brown Brian Lee | A-Award | 134,167.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).